FRIDAY 8 OCTOBER 2021 | 10th Trends in Medical Mycology

09:00

ECMM council meeting

12:00

Coffee break

Plenary Session 1 The 10th TIMM Anniversary

Chairs: Neil Gow, United Kingdom, FECMM & Martin Hoenigl, Austria, FECMM

12:30

PS 1.1 The life and death of diagnostic methods in mycology

Sybren de Hoog, the Netherlands, FECCM

12:50

PS 1.2 Highlights of clinical trials in medical mycology

George Petrikkos, Greece

13:10

PS 1.3 Celebration of Fungal Facts and Science

Adilia Warris, United Kingdom, FECMM

13:45

Parallel Symposia 1-4

Symposium 1 Diagnostics Endemic Mycoses

Chairs: Thuy Le, USA & Tadeja Matos, Slovenia

13:45

S01.1 Coccidioidomycosis: Diagnostics

Derek Bays, USA

14:05

S01.2 Novel Non-Culture Diagnostics for Talaromycosis

Thuy Le, USA

14:25

S01.3 Histoplasmosis

Alessandro Pasqualotto, Brazil, FECMM

14:45

S01.4 Molecular diagnosis of sporotrichosis from patients with subcutaneous lesions of Antioquia (Colombia) 1976 - 2021

Erika Sánchez Cifuentes, Colombia

15:00

S01.5 Ex-vivo and in-vivo production of ROS and cytokine profile of LASER-irradiated murine neutrophiles in infection by Paracoccidioides brasiliensis

Bruno José Nascimento Gomes, Brazil

Symposium 2 Engaging the public - medical mycology advocacy, policy and the general public

Chairs: Donna MacCallum, United Kingdom & Esther Segal, Israel, FECMM

13:45

S02.1 Strategies to change public perceptions of fungal disease

Lorna Barnes, United Kindom

14:05

S02.2 advocacy, policy

David Denning, United Kingdom, FECCM

14:25

S02.3 engaging public and politics in Low Middle Income Countries

Bright Ocansey, Ghana

14:45

S02.4 Onsite trainings to improve outcomes of People Living with HIV (PLHIV) in Sub-Saharan African countries

Aude Sturny-leclere, France

15:00

S02.5 Mucormycosis in Covid19 pandemic: Another foe joining hands with SARS-CoV-2 in India.

Jagdish Chander, India

Symposium 3 Clinical Risk and prevention of IFI in patients receiving biologics and targeted therapies

Chair: Jose Aguado, Spain, FECMM

13:45

S03.1 IFI in patients receiving biologics and targeted therapies: Which drugs and clinical situations really increases the risk?

Jose Aguado, Spain, FECMM

14:05

S03.2 Is antifungal prophylaxis necessary?

Malgorzata Mikulska, Italy, FECMM

14:25

S03.3 Biologic and targeted therapies for the treatment of IFI

Elham Khatamzas, Germany

14:45

S03.4 Immune dysregulation in psoriasis patients with skin or mucosal candidiasis during IL-17 or IL-(12)/23 inhibitor therapy

Mariolina Bruno, the Netherlands

Sponsored symposium 4 Update on new antifungals

More information on https://www.timm2021.org/sponsored-symposia/

15:15

Coffee break

15:30